PT  - JOURNAL ARTICLE
AU  - Kozik, V.
AU  - Reuken, P.
AU  - Utech, I.
AU  - Gramlich, J.
AU  - Stallmach, Z.
AU  - Demeyere, N
AU  - Stallmach, A.
AU  - Finke, K.
TI  - Assessment of subtle cognitive impairments in patients with post-COVID syndrome with the tablet-based Oxford Cognitive Screen-Plus (OCS-Plus)
AID  - 10.1101/2022.05.23.22275442
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.23.22275442
4099  - http://medrxiv.org/content/early/2022/05/23/2022.05.23.22275442.short
4100  - http://medrxiv.org/content/early/2022/05/23/2022.05.23.22275442.full
AB  - Background and objectives Cognitive symptoms persisting beyond 3 months following COVID-19 present a considerable disease burden. We aimed to establish a domain-specific cognitive profile of post-COVID syndrome, and relationships with clinical variables, to provide relevant information for outcome prediction and treatment decision-making.Methods We compared cognitive performance on the Oxford Cognitive Screen-Plus between a large post-COVID cohort (n = 282) and a socio-demographically matched healthy control group (n = 52). We assessed task- and domain-level dysfunction and relationships between clinical and patient-reported outcomes.Results Patients scored significantly lower on delayed verbal memory, attention, and executive functioning than healthy controls and in each of these domains, 10-20% of patients scored below cutoff. Delayed Memory was particularly affected and a rather small proportion of its variace was explained by hospitalization (β = -.67, p < .01) and age (β = -.03, p < .01; R2adj. = .06). Hospitalization further predicted attention performance (β = -.83, p < .001; R2adj. = .04).Interpretation Post-COVID syndrome is associated with long-term cognitive dysfunction, particularly in delayed verbal memory, attention, and executive functioning, relatively independent of original disease severity. Next, longitudinal investigation of the domain-dysfunctions in this cohort is needed to examine their trajectory.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe post-COVID Center was supported by the Thueringer Aufbaubank (2021 FGI 0060).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Friedrich-Schiller-University gave ethical approval for this study [amendment to 5082-02/17].I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.